Jefferies Financial Group Reiterates Buy Rating for Smith & Nephew (LON:SN)

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reaffirmed by Jefferies Financial Group in a research report issued to clients and investors on Friday, Digital Look reports. They presently have a GBX 1,500 target price on the stock. Jefferies Financial Group’s target price would indicate a potential upside of 42.59% from the company’s previous close.

Several other equities research analysts have also issued reports on SN. Royal Bank Of Canada decreased their price target on shares of Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research note on Thursday, August 6th. Shore Capital Group reissued a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a report on Tuesday, July 21st. Berenberg Bank decreased their target price on Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a research report on Friday, August 14th. Citigroup lowered Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. dropped their price target on Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a research report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,310.

Smith & Nephew Stock Performance

Shares of LON:SN opened at GBX 1,052 on Friday. The stock has a market cap of £11.53 billion, a P/E ratio of 37.88, a P/E/G ratio of 0.46 and a beta of 0.69. The business has a fifty day moving average of GBX 1,118.14 and a 200-day moving average of GBX 1,169.82. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.